Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from USAN

GlobeNewswire June 2, 2021

INmune Bio, Inc. to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and hosted by M-Vest on May 26th, 2021

GlobeNewswire May 24, 2021

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

GlobeNewswire May 5, 2021

INmune Bio, Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5

GlobeNewswire April 28, 2021

INmune Bio, Inc. Announces Participation in Fireside Chat at the B Riley Neurosciences Conference

GlobeNewswire April 26, 2021

INmune Bio, Inc. Announces Professor Mark Lowdell, PhD, CSO to Deliver Presentations at Two Upcoming Medical Meetings

GlobeNewswire March 22, 2021

INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021

GlobeNewswire March 8, 2021

INmune Bio, Inc. Announces Fourth Quarter and Full Year 2020 Results and Provides Business Update

GlobeNewswire March 4, 2021

INmune Bio, Inc. to Report Fourth Quarter and Full Year 2020 Financial Results and Provide a Corporate Update on Thursday, March 4

GlobeNewswire February 25, 2021

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer's Disease in Phase 1b Trial

GlobeNewswire January 21, 2021

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at 8 AM ET

GlobeNewswire January 13, 2021

Bexion Pharmaceuticals Announces the Addition of Dr. Raymond J. Tesi to Board of Directors

PR Newswire November 17, 2020

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor(TM) for Pulmonary Complications in COVID-19 Patients

GlobeNewswire November 9, 2020

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update

GlobeNewswire November 5, 2020

INmune Bio, Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on Thursday, November 5

GlobeNewswire October 29, 2020

INmune Bio, Inc. Presents Preliminary Phase I Data at 21st International Conference on Alzheimer's Drug Discovery

GlobeNewswire October 5, 2020

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Treatment Resistant Depression on Tuesday, September 29

GlobeNewswire September 23, 2020

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support Phase 2 Study of XPro1595 in Patients with Treatment Resistant Depression

GlobeNewswire September 16, 2020

INmune Bio, Inc. to Participate in Oppenheimer's Fall Healthcare Life Science & Med Tech Virtual Investor Summit, on September 23, 2020.

GlobeNewswire September 14, 2020

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering INKmune(TM) Therapy

GlobeNewswire September 3, 2020